Predicted protein targets (top 16)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | BRAF | P15056 | 5/20 | 0.78 |
| ▸ | MEN1 | O00255 | 1/20 | 0.47 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.47 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.46 |
| ▸ | CES1 | P23141 | 1/20 | 0.46 |
| ▸ | KCNQ3 | O43525 | 2/20 | 0.43 |
| ▸ | KCNQ2 | O43526 | 2/20 | 0.43 |
| ▸ | KCNE1 | P15382 | 2/20 | 0.43 |
| ▸ | KCNQ1 | P51787 | 2/20 | 0.43 |
| ▸ | KCNQ5 | Q9NR82 | 1/20 | 0.43 |
| ▸ | CSF1R | P07333 | 1/20 | 0.42 |
| ▸ | KCNK3 | O14649 | 1/20 | 0.42 |
| ▸ | KCNK9 | Q9NPC2 | 1/20 | 0.42 |
| ▸ | LCLAT1 | Q6UWP7 | 1/20 | 0.42 |
| ▸ | AURKA | O14965 | 1/20 | 0.42 |
| ▸ | GRM5 | P41594 | 1/20 | 0.41 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL4195968 | 0.95 | BRAF (0.70) | BRAFMEN1KMT2ASMN1; SMN2CES1 | |
| SCHEMBL4195680 | 0.91 | BRAF (0.74) | BRAFMEN1KMT2ACSF1R | |
| SCHEMBL4195857 | 0.90 | BRAF (0.66) | BRAFMEN1KMT2ASMN1; SMN2 | |
| SCHEMBL3979778 | 0.87 | BRAF (1.00) | BRAFMEN1KMT2AKCNQ3KCNQ2 | |
| SCHEMBL4203385 | 0.86 | BRAF (0.65) | BRAF | |
| SCHEMBL4198750 | 0.86 | BRAF (0.67) | BRAFMEN1KMT2ACSF1R | |
| SCHEMBL4204275 | 0.85 | BRAF (0.59) | BRAFMEN1KMT2ASMN1; SMN2 | |
| SCHEMBL4198711 | 0.81 | BRAF (0.59) | BRAFMEN1KMT2ASMN1; SMN2 | |
| SCHEMBL4191033 | 0.80 | BRAF (0.64) | BRAFMEN1KMT2A | |
| SCHEMBL4205760 | 0.79 | BRAF (0.68) | BRAF |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20090118276-A1 | THIENOPYRIMIDINES, THIENOPYRIDINES, AND PYRROLOPYRIMIDINES AS B-RAF INHIBITORS | WYETH (US) | 2009-05-07 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20090118276-A1 | THIENOPYRIMIDINES, THIENOPYRIDINES, AND PYRROLOPYRIMIDINES AS B-RAF INHIBITORS | BRAF, ARAF, RAF1 | BRAF 1/4885MEN1 4195/4885KMT2A 1956/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.